Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Y.D. More Investments Ltd

Y.D. More Investments Ltd raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 981.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 932,750 shares of the company’s stock after acquiring an additional 846,500 shares during the quarter. Teva Pharmaceutical Industries accounts for about 1.1% of Y.D. More Investments Ltd’s holdings, making the stock its 18th biggest position. Y.D. More Investments Ltd owned about 0.08% of Teva Pharmaceutical Industries worth $15,633,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Itau Unibanco Holding S.A. purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $453,000. Intech Investment Management LLC grew its position in Teva Pharmaceutical Industries by 0.3% during the second quarter. Intech Investment Management LLC now owns 350,399 shares of the company’s stock worth $5,873,000 after buying an additional 1,059 shares during the period. Creative Planning increased its holdings in Teva Pharmaceutical Industries by 23.8% in the second quarter. Creative Planning now owns 56,164 shares of the company’s stock valued at $941,000 after buying an additional 10,784 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Teva Pharmaceutical Industries by 36.1% during the 2nd quarter. SG Americas Securities LLC now owns 459,780 shares of the company’s stock valued at $7,706,000 after acquiring an additional 121,881 shares during the period. Finally, WealthShield Partners LLC boosted its stake in shares of Teva Pharmaceutical Industries by 6.6% during the 2nd quarter. WealthShield Partners LLC now owns 15,996 shares of the company’s stock worth $268,000 after acquiring an additional 996 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Down 0.6%

Shares of NYSE:TEVA opened at $25.40 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $29.13 billion, a P/E ratio of -158.73, a P/E/G ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $26.38. The stock’s fifty day simple moving average is $20.39 and its 200-day simple moving average is $18.22.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. The firm had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.86.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.49% of the stock is currently owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.